GlassScriptPhysician profile
Roger D Brown
NPI 1740204791
$2,273.34
in general payments reported to CMS, 2019-2025
28 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $208 · 2021: $209 · 2022: $114 · 2023: $443 · 2024: $431 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $555.36 | 2019-2025 | Sublocade |
| Novo Nordisk INC | $268.11 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $244.13 | 2021-2025 | Vraylar, Ubrelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $172.09 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $162.42 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $145.01 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $117.52 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.39 | 2025 | Caplyta |
| Antares Pharma, INC. | $58.51 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Braeburn INC. | $50.80 | 2023-2024 | Brixadi |
| Lundbeck LLC | $50.28 | 2023-2024 | Rexulti |
| Pfizer INC. | $31.52 | 2020 | |
| Halozyme INC | $29.62 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.26 | 2023 | Xifaxan, Trulance |
| Kyowa Kirin, INC. | $29.25 | 2024 | Crysvita |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $28.66 | 2020 | |
| Supernus Pharmaceuticals, INC. | $28.54 | 2022-2023 | Xyosted, Qelbree |
| Adlon Therapeutics L.P. | $25.84 | 2021 | |
| Jazz Pharmaceuticals INC. | $19.32 | 2020 | |
| Vanda Pharmaceuticals INC. | $19.07 | 2025 | Fanapt |
| Corium, LLC | $18.95 | 2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $17.68 | 2021 | |
| Tris Pharma INC | $17.48 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $17.32 | 2022 | |
| Clarus Therapeutics INC. | $14.12 | 2021 | |
| Nabriva Therapeutics, Plc | $12.48 | 2021 | |
| Kaleo, INC. | $12.39 | 2019 | |
| Genentech USA, INC. | $11.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.